Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.55 |
| ▸ | HPGD | P15428 | 8/20 | 0.55 |
| ▸ | TSHR | P16473 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22560903 | 0.86 | HSD17B10 (0.46) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL7594838 | 0.80 | HSD17B10 (0.60) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL29518250 | 0.79 | TSHR (0.40) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL22560894 | 0.79 | TSHR (0.40) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL18587207 | 0.79 | LMNA (0.47) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL31379545 | 0.79 | TSHR (0.40) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL22560910 | 0.79 | AHR (0.39) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL18586693 | 0.79 | LMNA (0.52) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL1093924 | 0.79 | TSHR (0.40) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 | |
| SCHEMBL1094353 | 0.79 | ALDH1A1 (0.39) | HSD17B10HPGDTSHRCYP3A4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309593-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12297311-B2 | Biaryl hydroxythiophene group IV transition metal polymerization with chain transfer capability | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12221508-B2 | Biaryl phenoxy group IV transition metal catalysts for olefin polymerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-11 | — | — | US | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20220169756-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169756-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3935091-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | Dow Global Technologies LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113748138-A | Biaryl hydroxythiophene group IV transition metal polymerization with chain transfer capability | 陶氏环球技术有限责任公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3898723-A1 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION | Dow Global Technologies LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113490695-A | Biarylphenoxy group IV transition metal catalysts for olefin polymerization | 陶氏环球技术有限责任公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020185494-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185494-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020131566-A1 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131566-A1 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2010087399-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | 第一三共株式会社 (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20060205751-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1648885-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009993-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205751-A1 | Novel compounds | KCNN2, KCNN3, KCNN1 | HSD17B10 1975/4885HPGD 851/4885TSHR 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.